More about

Gastroesophageal Cancer

News
January 27, 2025
1 min read
Save

Combination does not extend survival vs. chemotherapy in gastroesophageal cancer

Combination does not extend survival vs. chemotherapy in gastroesophageal cancer

The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced gastroesophageal adenocarcinoma, according to the agents’ manufacturers.

News
February 02, 2024
3 min read
Save

Major cancer surgery associated with ‘elevated’ risk for venous thromboembolism

Major cancer surgery associated with ‘elevated’ risk for venous thromboembolism

Patients who underwent cancer surgery had an increased risk for venous thromboembolism for up to 1 year after the procedure, results from a retrospective study published in JAMA Network Open showed.

News
September 13, 2023
3 min read
Save

Cancer death rate drops by 33%, AACR report shows

Cancer death rate drops by 33%, AACR report shows

Results from the American Association for Cancer Research’s annual Cancer Progress Report revealed that the age-adjusted overall cancer death rate in the U.S. fell by 33% between 1991 and 2020.

News
February 16, 2023
3 min read
Save

Pembrolizumab regimen extends survival in advanced gastric, gastroesophageal cancer

Pembrolizumab regimen extends survival in advanced gastric, gastroesophageal cancer

The addition of pembrolizumab to chemotherapy significantly extended survival among patients with advanced HER2-negative gastric or gastroesophageal junction cancer, according to results of the phase 3 KEYNOTE-859 study.

News
January 23, 2023
2 min read
Save

Tislelizumab regimen new first-line option for gastric, gastroesophageal cancer subgroup

Tislelizumab regimen new first-line option for gastric, gastroesophageal cancer subgroup

Tislelizumab plus chemotherapy demonstrated statistically significant and clinically meaningful improvements in OS vs. chemotherapy alone among patients with PD-L1-positive, advanced gastric or gastroesophageal junction adenocarcinoma.

News
January 20, 2023
2 min read
Save

Regorafenib extends survival in refractory advanced gastroesophageal cancer

Regorafenib extends survival in refractory advanced gastroesophageal cancer

Adding regorafenib to best supportive care significantly increased survival rates compared with placebo among patients with refractory advanced gastroesophageal cancer, results of the randomized, phase 3 INTEGRATE IIa trial showed.

News
January 27, 2022
2 min read
Save

Pembrolizumab remains effective in PD-L1-positive advanced gastric, gastroesophageal cancer

Pembrolizumab remains effective in PD-L1-positive advanced gastric, gastroesophageal cancer

First-line pembrolizumab remained effective, safe and noninferior to chemotherapy among certain patients with PD-L1-positive advanced gastric, gastroesophageal junction cancer, according to follow-up results of the KEYNOTE-062 study.

News
March 23, 2021
1 min read
Save

FDA approves Keytruda for esophageal, gastroesophageal carcinoma

FDA approves Keytruda for esophageal, gastroesophageal carcinoma

The FDA approved pembrolizumab in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with locally advanced or metastatic esophageal or gastroesophageal carcinoma.

News
September 03, 2020
3 min read
Save

Pembrolizumab appears promising for certain patients with gastric, gastroesophageal cancer

Pembrolizumab appears promising for certain patients with gastric, gastroesophageal cancer

First-line pembrolizumab appeared noninferior to chemotherapy and led to fewer adverse events among certain patients with advanced gastric or gastroesophageal junction cancer, according to results of the phase 3 KEYNOTE-062 study.

News
April 18, 2020
1 min read
Save

American Cancer Society awards research, training grants

American Cancer Society awards research, training grants

The American Cancer Society approved $36.1 million in funding for 79 research and training grants.